QLI (QLI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
QLI (QLI) trades at $5.41 with AI Score 46/100 (Grade C). Qilian International Holding Group Limited focuses on researching, developing, and producing active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivatives (TCMD) in China. Market cap: $38.7M, Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: May 4, 2026Analyst Coverage for QLI: QLI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates QLI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
QLI: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
QLI (QLI) Healthcare & Pipeline Overview
Qilian International Holding Group Limited researches, develops, and produces active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivatives (TCMD) in China. The company also manufactures and distributes fertilizers and sausage casings, positioning itself as a diversified player in the healthcare and agricultural sectors.
What Is the Investment Thesis for QLI?
Qilian International Holding Group Limited presents a complex investment thesis. The company's focus on APIs and TCMDs aligns with growing demand for both modern and traditional medicines. However, the company's negative profit margin of -16.7% raises concerns about its operational efficiency and cost management. The company's diversification into fertilizers and sausage casings adds complexity to its business model. The beta of 1.41 indicates higher volatility compared to the market. Investors should carefully evaluate the company's ability to improve profitability, manage its diverse operations, and navigate the regulatory landscape for pharmaceuticals and agricultural products in China.
Based on FMP financials and quantitative analysis
QLI Key Highlights
- Market Cap of $38.7M reflects its small size within the pharmaceutical industry.
- Negative Profit Margin of -16.7% indicates operational inefficiencies or high costs relative to revenue.
- Gross Margin of 1.3% suggests limited pricing power or high cost of goods sold.
- Beta of 1.41 indicates higher volatility compared to the broader market.
- No Dividend Yield reflects a lack of current income for investors.
Who Are QLI's Competitors?
QLI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ETST Earth Science Tech, Inc. | $0.14 | +0.07% | $40.3M | 61 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| MNNGF Baijin Life Science Holdings Limited | $0.07 | +0.00% | $58.0M | 63 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| SHIEF Shield Therapeutics plc | $0.08 | +0.00% | $84.8M | 62 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
| EMBC Embecta Corp. | $3.37 | -2.03% | $200M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are QLI's Key Strengths?
- Diversified product portfolio across healthcare and agriculture.
- Focus on traditional Chinese medicine derivatives (TCMD).
- Established presence in the Chinese market.
- Proprietary formulations for certain products.
What Are QLI's Weaknesses?
- Negative profit margin.
- Limited brand recognition outside of China.
- Reliance on a small number of key products.
- Small market capitalization.
What Could Drive QLI Stock Higher?
- Potential regulatory approvals for new pharmaceutical products.
- Expansion of sales and distribution network within China.
- Development of new traditional Chinese medicine derivatives (TCMD).
What Are the Key Risks for QLI?
- Negative return on equity (-16.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Increased competition from generic drug manufacturers.
- Stringent regulatory requirements for pharmaceutical production.
- Fluctuations in raw material prices.
- Negative profit margin impacting financial stability.
What Are the Growth Opportunities for QLI?
- Expansion of API Production: Qilian International can capitalize on the growing demand for APIs in China and globally. The global API market is projected to reach $292.7 billion by 2028, growing at a CAGR of 6.1%. By increasing its API production capacity and diversifying its API portfolio, Qilian International can capture a larger share of this market. This expansion could involve strategic partnerships with pharmaceutical companies or investments in advanced manufacturing technologies.
- Increased TCMD Product Development: The market for traditional Chinese medicine derivatives (TCMD) is expanding, driven by consumer interest in natural and holistic healthcare solutions. Qilian International can invest in research and development to create new TCMD products and formulations. This includes conducting clinical trials to validate the efficacy of its TCMD products and obtaining regulatory approvals for their sale in China and international markets. The timeline for new product development can range from 2-5 years.
- Geographic Expansion within China: Qilian International can expand its sales and distribution network to reach new geographic markets within China. This can involve establishing partnerships with regional distributors, opening new sales offices, and participating in trade shows and industry events. The company can focus on regions with high demand for its licorice products, oxytetracycline tablets, and TCMD products. Geographic expansion can increase revenue and reduce reliance on its existing customer base.
- Strategic Partnerships in Agriculture: The company's diversification into fertilizers provides an opportunity to capitalize on the growing demand for organic and compound fertilizers in China's agricultural sector. Qilian International can form strategic partnerships with agricultural companies, farmers' cooperatives, and government agencies to promote the use of its Xiongguan fertilizers. This includes conducting field trials to demonstrate the benefits of its fertilizers and providing technical support to farmers. These partnerships can increase sales and market share in the agricultural sector.
- Product Diversification in Healthcare: Qilian International can diversify its healthcare product portfolio by developing and marketing new pharmaceutical products and medical devices. This can involve licensing or acquiring new technologies, conducting clinical trials, and obtaining regulatory approvals. The company can focus on therapeutic areas with unmet medical needs, such as cardiovascular diseases, diabetes, and infectious diseases. Product diversification can reduce reliance on its existing product lines and increase revenue growth.
What Opportunities Does QLI Have?
- Expansion into new geographic markets.
- Development of new pharmaceutical products and medical devices.
- Increased demand for organic and compound fertilizers.
- Strategic partnerships with larger pharmaceutical companies.
What Threats Does QLI Face?
- Intense competition from generic drug manufacturers.
- Stringent regulatory requirements for pharmaceutical production.
- Fluctuations in raw material prices.
- Economic slowdown in China.
What Are QLI's Competitive Advantages?
- Proprietary formulations for traditional Chinese medicine derivatives (TCMD).
- Established relationships with pharmaceutical companies and distributors in China.
- Diversified product portfolio across healthcare and agriculture.
- Access to local resources for licorice and other raw materials.
What Does QLI Do?
Qilian International Holding Group Limited, incorporated in 2019 and based in Jiuquan, China, operates within the healthcare sector, focusing on the research, development, and production of active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivatives (TCMD). The company's product portfolio includes licorice products such as Gan Di Xin (an antitussive and expectorant), Qilian Shan Licorice Extract (used in traditional licorice tablets), and Qilian Shan licorice liquid extract (used in compound licorice oral solutions). Additionally, Qilian International offers Qilian Shan oxytetracycline tablets and APIs, used to prevent and treat diseases in animals and humans. The company also produces TCMD products like Ahan antibacterial paste for skin diseases, and heparin products for cardiovascular and cerebrovascular medications. Beyond pharmaceuticals, Qilian International manufactures Zhu Xiaochang sausage casings and Xiongguan organic and organic-inorganic compound fertilizers, diversifying its revenue streams across both healthcare and agriculture. This diversification strategy aims to leverage traditional Chinese medicine and agricultural resources in the region.
What Products and Services Does QLI Offer?
- Researches and develops active pharmaceutical ingredients (APIs).
- Produces traditional Chinese medicine derivatives (TCMD).
- Manufactures licorice products for pharmaceutical applications.
- Offers oxytetracycline tablets and APIs for animal and human health.
- Produces Ahan antibacterial paste for skin diseases.
- Manufactures heparin products for cardiovascular and cerebrovascular treatments.
- Produces Zhu Xiaochang sausage casings for culinary use.
- Manufactures Xiongguan organic and organic-inorganic compound fertilizers.
How Does QLI Make Money?
- Develops and manufactures APIs and TCMDs.
- Sells pharmaceutical products, including licorice extracts and oxytetracycline.
- Manufactures and sells agricultural fertilizers.
- Generates revenue through the sale of sausage casings.
What Industry Does QLI Operate In?
Qilian International Holding Group Limited operates in the specialty and generic drug manufacturing industry, which is characterized by intense competition and pricing pressures. The Chinese pharmaceutical market is experiencing growth, driven by increasing healthcare expenditure and an aging population. The company's focus on traditional Chinese medicine derivatives (TCMD) positions it within a segment that benefits from cultural preferences and government support for traditional medicine. However, the company also faces competition from established generic drug manufacturers and evolving regulatory standards for pharmaceutical production and quality control.
Who Are QLI's Key Customers?
- Pharmaceutical companies that use its APIs and licorice extracts.
- Medical preparation companies that use its licorice liquid extract.
- Farmers who use its organic and compound fertilizers.
- Consumers who purchase its oxytetracycline tablets and Ahan antibacterial paste.
- Food processing companies that use its sausage casings.
QLI Valuation & Market Position
With a $38.7M market cap, QLI sits in the micro-cap segment of the market. Relative to its peer group, QLI's quantitative score of 46/100 is below the peer average of 63/100.
ROE -16%Key Financial Metrics
Return on equity for QLI stands at -16.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -15.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.18 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
QLI's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 6.42 places it in the safe zone, indicating low near-term bankruptcy risk.
QLI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in QLI's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting innovative product developments and growing market interest.
- Analysts have noted an increase in demand for QLI's offerings, reflecting a favorable market environment for the company.
- Social media buzz shows a rising number of endorsements from industry influencers, enhancing QLI's reputation and reach.
Bear Case
- Concerns have emerged regarding potential regulatory challenges that could impact QLI's operations, creating uncertainty among investors.
- Some community members express skepticism about QLI's scalability, questioning whether current growth can be sustained long-term.
- Recent negative news coverage has raised doubts about QLI's management decisions, leading to a more cautious outlook among traders.
- Market sentiment remains mixed, with bearish views highlighting competitive pressures that could hinder QLI's market share.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
QLI Latest News
No recent news available for QLI.
QLI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for QLI.
Price Targets
Wall Street price target analysis for QLI.
QLI MoonshotScore
What does this score mean?
The MoonshotScore rates QLI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Chen Xin
CEO
Chen Xin is the Chief Executive Officer of Qilian International Holding Group Limited. Information regarding Chen Xin's detailed career history, education, and previous roles is not available in the provided data. Therefore, a comprehensive background cannot be provided at this time.
Track Record: Due to limited information, specific achievements, strategic decisions, and company milestones under Chen Xin's leadership cannot be detailed. Further information is needed to assess Chen Xin's track record at Qilian International Holding Group Limited.
QLI Healthcare Stock FAQ
What does the AI Score mean for QLI?
QLI holds an AI Score of 46/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Qilian International Holding Group Limited focuses on researching, developing, and producing active pharmaceutical ingredients (APIs) and traditional Chinese medicine derivatives (TCMD) in China …
What does Qilian International Holding Group Limited do?
Qilian International Holding Group Limited engages in the research, development, production, and sale of active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), fertilizers, and sausage casings. The company's healthcare segment focuses on licorice products, oxytetracycline tablets, Ahan antibacterial paste, and heparin products. Its agricultural segment produces organic and organic-inorganic compound fertilizers. Additionally, it manufactures Zhu Xiaochang sausage casings.
What do analysts say about QLI stock?
Analyst coverage of Qilian International Holding Group Limited (QLI) is currently limited, making a consensus view unavailable. Key valuation metrics such as price-to-earnings (P/E) ratio and price-to-sales (P/S) ratio should be considered in light of the company's negative profit margin.
What are the main risks for QLI?
Qilian International Holding Group Limited faces several key risks. The company's negative profit margin raises concerns about its financial sustainability. Intense competition from generic drug manufacturers and evolving regulatory standards for pharmaceutical production pose challenges. Fluctuations in raw material prices, particularly for licorice and other key ingredients, can impact profitability.
What are the key factors to evaluate for QLI?
QLI holds an AI score of 46/100 (low). Not financial advice.
How frequently does QLI data refresh on this page?
QLI's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven QLI's recent stock price performance?
QLI moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio across healthcare and agriculture. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider QLI overvalued or undervalued right now?
QLI has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research QLI before investing?
Before investing in QLI, research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis.
- Lack of analyst coverage restricts consensus view on stock performance.